What are the treatment options for colorectal cancer? - Dr. Tanios Bekaii-Saab

(1:7)

Tanios Bekaii-Saab, MD: Mechanisms of Action in Regorafenib

(1:12)

Tanios Bekaii-Saab, MD: Experience With Patients on Bevacizumab Plus Chemotherapy

(1:22)

Tanios Bekaii-Saab, MD, FACP, offers opinion on the updated KEYNOTE-177 as presented at ASCO GI 2021

(4:39)

Tanios Bekaii-Saab, MD: Impeding RAS Mutation Testing

(1:59)

Tanios Bekaii Saab, MD: Treatment Toxicities and Quality of Life

(2:56)

Tanios Bekaii-Saab, MD: Chemotherapy Side-Effects

(2:13)

Tanios Bekaii-Saab, MD: Bevacizumab Side-Effects

(2:21)

Tanios Bekaii-Saab, MD: Clinical Importance of RAS Mutations

(1:14)

What are the symptoms of colorectal cancer? - Dr. Tanios Bekaii-Saab

(31)

Tanios Bekaii-Saab, MD, discusses oral chemo in adjuvant and advanced CRC treatment during COVID

(3:16)

Dr. Tanios Bekaii-Saab on New Agents to Treat Colorectal Cancer

(2:22)

Tanios Bekaii Saab, MD: RAS Mutations and the Sequence of Therapies

(5:8)

Tanios Bekaii-Saab MD, FACP describes deintensification strategies for mCRC patients during COVID-19

(3:31)

Tanios Bekaii-Saab, MD on outcomes of CALGB/SWOG 80404 and potential impact

(51)

Dr Bekaii-Saab on Frontline Treatment Considerations for BRCA1/2+ Pancreatic Cancer

(1:45)

Kicking Cancer's KRAS Expert Series: A Conversation with Dr. Tanios Bekaii-Saab and Terri Conneran

(1:32:1econd)

Tanios Bekaii-Saab, MD: Reinitiating Regorafenib in Patients with mCRC

(28)

Tanios Bekaii-Saab, MD: First-Line Treatments in Unresectable Colon Cancer

(2:17)

Tanios Bekaii-Saab MD, FACP, discusses changes in treatment for CRC patients resulting from COVID-19

(6:43)